

DIGNITANA

Clinically superior scalp cooling

Q3  2018
INTERIM REPORT

Contents

Results and financial position	3
CEO comments	5
The company	6
The market	7
Business model	9
The product and product development	10
Financial information	11
Forward-looking statements	12
Risk factors	12
The share	13
Board assurance	14
Financial figures	
Income Statement – Dignitana Group	15
Balance Sheet – Dignitana Group	16
Changes in Equity – Dignitana Group	18
Statement of Cash Flows – Dignitana Group	19
Income Statement – Dignitana AB, Parent Company	20
Balance Sheet – Dignitana AB, Parent Company	21
Policies for preparation of the financial report	23
Financial calendar	23
Contact information	23



Results and financial position

Significant events during the period

- Sales for the period amounted to 10,293 TSEK, \$1,150 KUSD, an increase of 125 percent compared to the same period in 2017 and an increase of 14 percent compared to the second quarter 2018.
- EBITDA amounted to (3,459) TSEK, (\$386 KUSD), a 56 percent improvement compared to the same period in 2017.
- 6 units were sold to facilities in countries outside the U.S.
- Contracts for 7 locations in the U.S. were signed.
- Third quarter treatment revenue in the U.S. increased over second quarter 2018.
- In July Dignitana AB registered a new wholly-owned subsidiary, Dignitana S.r.l (Società a responsabilità limitata), as a new Italian entity to facilitate contracting with public health facilities in Italy.

Significant events after the period

- Contracts for 10 locations in the U.S. have been signed since 30 September.
- 8 units sold outside the U.S. since 1 October 2018.
- On 8 October Dignitana announced that Mr. Greg Dingizian, via his Adma Förvaltnings AB investment vehicle, has accumulated a 4,200,000 share position in the company. The share purchases of Adma Förvaltnings AB represent 10.4 percent of the outstanding common shares of the company.
- An agreement has been reached with Konica-Minolta and Beijing University Cancer Hospital to perform a limited usage trial of the DigniCap device to evaluate efficacy when compared to manual gel caps. The trial is scheduled to begin during the fourth quarter 2018.
- The company has announced a combination of a directed equity and rights issue to obtain 30 MSEK. This transaction is scheduled to be completed by mid-December.

Financial results in brief

Key Ratios

DIGNITANA GROUP	Q3 2018	Q3 2017	Q1-Q3 2018	Q1-Q3 2017	Full year 2017
Net revenues, TSEK	10,166	4,550	25,039	16,436	22,941
Total revenues TSEK	10,293	4,565	25,303	16,594	23,133
Net profit after financial items, TSEK	(6,349)	(10,338)	(20,651)	(29,261)	(42,355)
Cash and bank balances, TSEK	4,562	6,192	4,562	6,192	1,018
Earnings per share before and after dilution, SEK	(0.16)	(0.51)	(0.51)	(1.44)	(2.10)

DIGNITANA AB	Q3 2018	Q3 2017	Q1-Q3 2018	Q1-Q3 2017	Full year 2017
Net revenues, TSEK	6,810	3,283	18,537	13,231	18,300
Total revenues TSEK	6,937	3,299	18,800	13,390	18,490
Net profit after financial items, TSEK	(5,975)	(10,257)	(19,933)	(29,357)	(42,277)
Cash and bank balances, TSEK	3,645	9,157	3,645	9,157	606

CEO comments

The third quarter of 2018 was another significant step forward for the company as revenues and installations increased to record levels in the U.S. and globally.

Quarterly revenues for the third period continued to grow with increased revenue from new and existing facilities as well as sales to non-U.S. treatment centers. Third quarter 2018 revenue increased to 10,293 TSEK, representing a 14 percent increase over second quarter 2018 and a 125 percent increase over second quarter 2017.

Dignitana has now had 10 consecutive quarters of increasing revenue from the United States. Additional revenue attributable to non-U.S. unit sales and maintenance helped the company reach record high revenue for the period.

A significant amount of financial and corporate resources have been allocated to the new product development effort. While an expensive and lengthy endeavor, I am confident that the company is now moving quickly in the right direction. We are proud of the advancements integrated into the new device design and greatly look forward to introducing the new unit to the market in early 2019.



To fund continued growth Dignitana requires additional working capital. To that end, today we have announced a combination of a directed equity and rights issue to obtain 30 MSEK. This transaction is scheduled to be completed by mid-December. Fully subscribed, the company will receive SEK 30.8M before issue costs. The Company's opinion is that the current offering will be sufficient to achieve three objectives: fund the Company's operations throughout 2019; enable the Company to commercialize the new generation of the DigniCap system; and strengthen the Company's financial position.

As Dignitana expands our business globally we continue to make investments in products and personnel necessary to take advantage of the enormous opportunity ahead. The company is establishing a balanced sales effort using distributors in some regions and direct sales to medical facilities in Europe and select other markets. This new and increasingly important revenue stream confirms the substantial global opportunities for the company.

Our transition over the past year has been significant. Each quarter the company makes continued progress toward attaining the ambitious goals we have set. As we continue to move forward, we are constantly working to bring innovation and change to our industry, patients and our partner sites. The support of our shareholders is critical to our efforts and this is a responsibility we do not take lightly. Together we look forward to reaching new milestones in the next quarter and beyond.

A handwritten signature in blue ink that reads "William Cronin". The signature is fluid and cursive, with a large 'W' and 'C'.

William Cronin, CEO
Dignitana AB

The company

Dignitana is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North. The company develops, produces and markets **The DigniCap® Scalp Cooling System**. It is a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort. In 2017, Dignitana received an expanded clearance from the FDA, allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lung and other tissues.





The market

Cancer is a leading cause of death worldwide and the number of people who develop cancer is continuing to increase. According to the World Health Organization (WHO), 14.1 million people are annually diagnosed with cancer. One of the most common therapies for cancer is chemotherapy. Globally an estimated 20,000 clinics offer chemotherapy, providing a total of over ten million chemotherapy treatments per year.

The side effects of chemotherapy can make treatment very difficult. As a visible reminder of the disease, hair loss is often identified as one of the most distressing side effects of chemotherapy. Physicians estimate that approximately ten percent of patients decline the prescribed chemotherapy out of fear of losing their hair.

Dignitana's DigniCap Scalp Cooling System is primarily used today during the treatment of breast cancer, the most common type of cancer in women worldwide with the World Cancer Research Fund reporting over

1.7 million diagnosed cases annually. Dignitana estimates that 60 percent of breast cancer patients can be treated with DigniCap. In the U.S. alone there are approximately 800,000 patients with solid tumor cancers diagnosed each year.

The DigniCap Scalp Cooling System was invented in Sweden and has been marketed since 2001. It is available in Australia, Belgium, Canada, Colombia, France, Germany, Dubai, Italy, Iraq, Mexico, Qatar, Romania, Switzerland, The United Kingdom and many other countries.

The United States is the leading market for medical devices in the world. Growth in the U.S. is critical, and the company follows a strategic approach to ensure effective use of resources and to optimize clinical success at the locations offering DigniCap. The sales model in the U.S. involves diversified revenue sources with the pay-per-treatment revenue as the largest contributing source.

Contracts for 7 new U.S. facilities were signed during the third quarter, bringing the total to 107 locations representing 147 machines.

Since initiating sales in the U.S., the company has focused on multiple location oncology practices, allowing one site in the group to demonstrate the feasibility and efficacy of the treatment, with additional locations joining later. This strategy is now paying off with several smaller practices expanding, as well as the large Florida Cancer Specialists group adding multiple locations in the third quarter.

The global reach of Dignitana is expanding as well, with 6 machines sold this quarter directly to Italy, The Czech Republic and Mexico bringing the year-to-date total number of units sold globally to 17.


In April, Dignitana acquired 70 medical facilities in 11 countries from Sysmex, our former distributor. That footprint has now grown to 80 locations in these same 11 countries. Our team continues to work with these

facilities to provide prompt and reliable service, and several locations have added service agreements as a result of our proactive account management.

Interest in scalp cooling in the Middle East is building and work continues with our distributor, Tesla Medical Solutions, to finalize documentation to enable sales in Saudi Arabia, Oman, Kuwait, Armenia and Egypt. Tesla has, to date, placed DigniCap devices in Iraq, Qatar and Dubai.

For several years Dignitana has been in discussion with Konica Minolta in preparation for the introduction of DigniCap to the large market in Asia. The first step in commercialization in Asia is the clinical trial that we are initiating with Beijing University Cancer Hospital. This trial represents the first clinical evaluation of scalp cooling on an exclusively Asian population.





Business model

The company has four primary revenue streams: treatment fees to patients (pay-per-treatment using leased machines); machine sales; service agreements; and leasing fees. In the United States the largest opportunity for growth is through our pay-per-treatment

model. For those markets that have not yet adopted a pay-per-treatment model, the focus is on creating a more sustainable recurring revenue model in the form of leases and service agreements.



The product and product development

Cancer is the most common malignancy worldwide and treatment often includes chemotherapy. Hair loss remains a frequent side effect of chemotherapy and is rated by patients as one of the most distressing impacts from treatment, affecting quality of life, ability to return to work, and self-image. The DigniCap Scalp Cooling System has been clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumor cancers. The current generation DigniCap has been on the market since 2009. In addition to occasional software upgrades, recent enhancements to the system include the DigniTherm Click Cap, a product extension engineered to improve ease of use and enhance cap fit to improve patient outcomes. The U.S. launch of the

Click Cap was completed in March 2018, and during the second and third quarters there was a steady increase in utilization as facilities used the new cap and became familiar with the improvements.

The company is currently engaged in a significant product development initiative to launch the next generation scalp cooling device. This system is a smaller, single-patient device providing improved ease of use for both the patient and clinician. Development of the machine is progressing on schedule and at a rapid pace. The introduction of the new system to the market (pending FDA clearance) is planned for early 2019, with a preview of the device planned for December 2018 at the San Antonio Breast Cancer Symposium.

Financial information

Group revenues are generated by direct sales of systems, pay-per-treatment fees, leased machines, service agreements and other revenue such as spare parts sales. Dignitana Group revenues increased 125 percent from 4,565 TSEK in third quarter 2017 to 10,293 TSEK third quarter 2018. Group revenues in third quarter 2018 increased 14 percent from second quarter 2018.

Dignitana, Inc. continues to grow quarterly revenue with a 44 percent increase in revenue from the third quarter 2017 to third quarter 2018. Quarterly growth over the last 8 quarters has averaged 20 percent.

As compared to the same quarter last year, costs year over year decreased from 267 percent to 122 percent as a percentage of revenue.


Travel expense, revenue sharing, training, maintenance and other costs have resulted in additional expense related to sales at some European sites.

Cost of goods sold include the cost of the finished goods sold during the period. Income arising from the sale of goods is recognized when the goods have been delivered and ownership has been transferred to the buyer. In the U.S. Dignitana, Inc. does not sell the device directly to the end customer as various lease models are used instead.

In early November the company accessed \$350 KUSD from its existing line of credit with Union Business Leasing with the option to draw an additional \$150 KUSD before year end. The company may also draw up to an additional \$500 KUSD in first quarter 2019 for working capital purposes.

Dignitana revenues and costs are comprised of different currencies such as U.S. Dollars, Euros, and other currencies. Foreign exchange translation differences are found on the income statement under results from financial investments.

Revenues Per Quarter – Dignitana, Inc. (USD)



Forward-looking statements

This report may contain statements, estimates or projections that constitute “forward-looking statements”. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will” and similar expressions identify forward-looking statements, which

generally are not historical in nature. Forward looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Risk factors

An investment in securities is associated with risk. Dignitana’s activities are affected, and may be affected, by a number of factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and such which has no specific connection with the Company. Below, without any particular order and without claim to be exhaustive, are some of the risk factors and circumstances which are considered essential for Dignitana’s operations and future development. The risks described below are not a conclusive list of the risks which the Company and its shareholders may be exposed to. Additional risks that are not currently known to the Company or that the Company currently does not consider essential may also be of significant importance to Dignitana’s business, financial position and results. Such risks may also cause the Company’s share price to fall sharply and investors may lose all

or part of their investment. In addition to this section, investors should also consider the other information contained in the Prospectus as a whole and implement one general environmental assessment.

The non-conclusive list of the Company’s risks concerns (but are not limited to): Patents, Key Personnel, Growth Management, Restructuring, Development Costs, Competitors, Capital Bonds, Depending on Individual Customers, Customers, Authorization and Registration, Chemotherapy Without Side Effects, Distributors and Manufacturers, Profitability and Future Capital Needs, Political Risk, Regulatory or Change of Laws, Disputes and Currency Risks.

For a detailed explanation of these risk factors view the December 2017 Company Prospectus posted at <https://investor.dignitana.com/new-issues/>


The share

The total number of outstanding shares at the close of the period was 40,548,224.

The share has been listed on the Nasdaq First North since 30 November 2011 after having been listed at Aktietorget since June 2009. It is traded under the DIGN ticker.

There are 265,000 warrants in the company. The warrants carry the right to purchase 165,000 shares in the period June 1 to 30, 2019 and 100,000 shares in the period June 1 to 30 June 2020 and will, on full exercise, increase the company share capital by SEK 265,000.

Erik Penser Bank is the company's Certified Adviser.



Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 16 November 2018

Dignitana AB (publ) Board of Directors

Thomas Kelly
Chairman

William Cronin
Director and CEO

Mikael Wahlgren
Director and
Deputy Managing Director

Ingrid Atteryd Heiman
Director

This interim report has not
been audited by the company auditors.

Income Statement – Dignitana Group

SEK

DIGNITANA GROUP	Q3 2018	Q3 2017	Q1-Q3 2018	Q1-Q3 2017	Full year 2017
Operating Income					
Revenue	10,165,964	4,550,211	25,038,807	16,435,987	22,940,627
Own work capitalized	–	–	–	14,975	14,975
Other income	127,268	14,906	263,852	143,485	177,763
Total Operating Income	10,293,231	4,565,117	25,302,660	16,594,447	23,133,365
Cost of Goods Sold					
Goods for Resale	1,192,059	294,280	2,627,484	2,899,527	3,724,858
Gross Profit	9,101,172	4,270,837	22,675,176	13,694,920	19,408,507
Operating expenses					
Other external expenses	7,534,486	6,736,087	20,071,463	20,231,150	28,419,237
Personnel expenses	5,025,253	5,437,073	15,532,415	16,580,498	24,687,021
Other Operating expense	685	6,063	28,292	45,150	54,808
Total operating expenses	12,560,424	12,179,223	35,632,169	36,856,798	53,161,066
Operating profit (loss) - EBITDA	(3,459,252)	(7,908,386)	(12,956,993)	(23,161,878)	(33,752,559)
Depreciation of tangible and intangible assets	1,975,650	1,731,870	5,923,223	4,707,215	6,761,746
Operating profit (loss) after depreciation - EBIT	(5,434,902)	(9,640,256)	(18,880,216)	(27,869,093)	(40,514,305)
Result from financial investments					
Interest income and similar items	7,137	165	598,059	1,831	1,896
Interest expenses and similar items	(921,233)	(698,327)	(2,368,496)	(1,393,335)	(1,842,255)
Total income (loss) from financial investments	(914,096)	(698,162)	(1,770,437)	(1,391,504)	(1,840,359)
Net profit (loss) after financial items	(6,348,998)	(10,338,418)	(20,650,653)	(29,260,597)	(42,354,664)
Corporate Taxes					245,244
Results for the Period	(6,348,998)	(10,338,418)	(20,650,653)	(29,260,597)	(42,599,908)
Total shares at the period-end before and after dilution ¹	40,548,224	20,274,112	40,548,224	20,274,112	20,274,112
Average number of shares before and after dilution ¹	40,548,224	20,274,112	40,548,224	20,274,112	20,274,112
Earnings per share before and after dilution ¹	(0.16)	(0.51)	(0.51)	(1.44)	(2.10)

1) no dilution

Balance Sheet – Dignitana Group

SEK

STATEMENT OF FINANCIAL POSITION	2018-09-30	2017-09-30	2017-12-31
Fixed Assets			
<u>Intangible assets</u>			
Capitalized expenses for development, net	14,064,100	12,204,317	11,399,905
<u>Tangible assets</u>			
Equipment, tools and installations, net	15,980,556	17,069,290	19,355,859
Total Fixed Assets	30,044,656	29,273,607	30,755,764
Current Assets			
<u>Inventories and similar</u>			
Finished goods and goods for resale	4,093,028	4,267,622	2,567,773
Advance payment to suppliers	2,798,327	74,345	276,062
	6,891,355	4,341,967	2,843,835
<u>Current Receivables</u>			
Accounts Receivable	7,704,937	3,094,569	2,974,624
Current Tax Assets	12,184	414,420	219,880
Other current receivables	–	1,205,989	43,927,775
Prepaid expenses and accrued income	1,385,715	615,684	557,422
	9,102,836	5,330,662	47,679,701
<u>Cash and Bank Balances</u>	4,561,721	6,192,011	1,017,957
Total Current Assets	20,555,913	15,864,640	51,541,493
Total Assets	50,600,569	45,138,247	82,297,257

Balance Sheet – Dignitana Group, continued

SEK

STATEMENT OF FINANCIAL POSITION	2018-09-30	2017-09-30	2017-12-31
Equity and Liabilities			
Equity			
<u>Restricted equity</u>			
Share Capital (40,528,224 shares par value SEK 1, previous year 20,274,112)	40,548,224	20,274,112	20,274,112
Unregistered share capital	–	–	20,274,112
Fund for development expenses	2,635,796	2,635,796	2,635,796
	43,184,020	22,909,908	43,184,020
<u>Non-restricted equity</u>			
Other paid-in capital	7,867,606	33,006,092	50,561,848
Results for the period	(20,650,653)	(29,260,597)	(42,599,908)
	(12,783,046)	3,745,495	7,961,940
Total Equity	30,400,974	26,655,403	51,145,960
Current Liabilities			
Accounts payable	5,859,292	4,409,318	5,090,671
Other current liabilities	970,792	419,627	431,425
Liabilities to credit institutions	5,766,364	–	5,000,000
Accrued expenses and deferred income	4,511,030	2,224,074	9,751,101
Total current liabilities	17,107,478	7,053,019	20,273,197
Long Term Liabilities			
Liabilities to credit Institutions	3,092,117	11,429,825	10,878,100
Total Equity and Liabilities	50,600,569	45,138,247	82,297,257

Changes in Equity – Dignitana Group

SEK

	Q1-Q3 2018	Q1-Q3 2017	Full Year 2017
Opening balance	51,145,960	55,870,277	55,870,277
New Share Issue	–	–	–
Unregistered Share Issue	–	–	42,575,635
Issue expenses	–	–	(4,772,032)
Subscribed warrants	–	124,000	124,000
Translation difference on consolidation Results for the period	(94,334)	(78,277)	(52,012)
Results through the end of the period	(20,650,653)	(29,260,597)	(42,599,908)
Closing balance	30,400,973	26,655,403	51,145,960

Statement of Cash Flows – Dignitana Group

SEK

	Q3 2018	Q3 2017	Q1-Q3 2018	Q1-Q3 2017	Full year 2017
Operating Activities					
Operating income before financial items	(5,434,902)	(9,640,256)	(18,880,216)	(27,869,093)	(40,514,305)
Adjustments for items not affecting cash flows	1,975,650	1,731,870	5,923,223	4,692,240	7,210,315
Interest received and similar items	7,137	165	598,059	1,831	1,896
Interest paid and similar items	(921,233)	(292,926)	(2,368,496)	(353,625)	(622,412)
Income tax paid	–	–	–	–	(105,478)
	(4,373,348)	(8,201,147)	14,727,430	(23,528,647)	(34,029,984)
Changes in inventories	(2,098,438)	(2,629,623)	(4,047,520)	(11,104,690)	(363,242)
Changes in other current receivables	(887,480)	1,206,211	38,483,288	(395,064)	(704,973)
Changes in other current liabilities	6,084,780	(585,418)	(3,165,719)	(1,951,535)	1,631,606
Cash flows from operating activities	(1,274,486)	(10,209,977)	16,542,618	(36,979,936)	(33,466,593)
Investing Activities					
Acquisition of fixed assets	(3,029,397)	(248,523)	(5,212,115)	(1,167,973)	(14,411,521)
Cash flows from investing activities	(3,029,397)	(248,523)	(5,212,115)	(1,167,973)	(14,411,521)
Financing Activities					
New share issue	–	–	–	–	–
Issuance costs	–	–	–	–	(290,574)
Subscribed warrants	–	124,000	–	124,000	124,000
Long Term Liabilities	(1,526,822)	6,429,825	(7,785,983)	11,429,825	16,282,187
Cash flows from financial activities	(1,526,822)	6,553,825	(7,785,983)	11,553,825	16,115,613
Cash flows in the period	(5,830,706)	(3,904,675)	3,544,520	(26,594,084)	(31,762,501)
Cash and cash equivalents at start of the period	10,368,236	10,120,878	1,017,957	32,864,372	32,864,372
Translation difference on cash and cash equivalents	24,191	(24,192)	(756)	(78,277)	(83,914)
Cash and cash equivalents Period End	4,561,721	6,192,011	4,561,721	6,192,011	1,017,957

Income Statement – Dignitana AB, Parent Company

SEK

DIGNITANA AB, PARENT COMPANY	Q3 2018	Q3 2017	Q1-Q3 2018	Q1-Q3 2017	Full year 2017
Operating Income					
Revenue	6,810,199	3,283,058	18,536,545	13,231,175	18,300,358
Own work capitalized	–	–	–	14,975	14,975
Other income	126,834	15,792	263,247	143,485	174,783
Total Operating Income	6,937,033	3,298,850	18,799,792	13,389,635	18,490,116
Cost of Goods Sold					
Goods for Resale	1,192,059	294,280	2,627,484	2,899,527	3,724,858
Gross Profit	5,744,973	3,004,570	16,172,308	10,490,108	14,765,258
Operating expenses					
Other external expenses	8,753,822	8,763,595	26,817,544	26,388,782	36,998,667
Personnel expenses	477,108	2,311,852	2,884,144	7,615,564	11,949,482
Other Operating expense	685	6,063	28,292	45,150	54,808
Total operating expenses	9,231,614	11,081,510	29,729,979	34,049,496	49,002,957
Operating profit (loss) - EBITDA	(3,486,641)	(8,076,940)	(13,557,671)	(23,559,388)	(34,237,699)
Depreciation and amortization	1,923,380	1,701,305	5,800,535	4,623,870	6,652,242
Operating profit (loss) after depreciation - EBIT	(5,410,021)	(9,778,245)	(19,358,206)	(28,183,258)	(40,889,941)
Result from financial investments					
Interest income and similar items	7,137	–	598,059	26	–
Interest expenses and similar items	(572,585)	(478,445)	(1,173,021)	(1,173,453)	(1,387,321)
Total income from financial investments	(565,448)	(478,445)	(574,962)	(1,173,427)	(1,387,321)
Net profit (loss) after financial items	(5,975,469)	(10,256,690)	(19,933,168)	(29,356,685)	(42,277,262)
Corporate Taxes	–	–	–	–	–
Results for the Period	(5,975,469)	(10,256,690)	(19,933,168)	(29,356,685)	(42,277,262)

Balance Sheet – Dignitana AB, Parent Company

SEK

STATEMENT OF FINANCIAL POSITION	2018-09-30	2017-09-30	2017-12-31
Fixed Assets			
<u>Intangible assets</u>			
Capitalized expenses for development, net	14,046,430	12,908,719	11,399,905
<u>Tangible assets</u>			
Equipment, tools and installations, net	15,621,203	14,412,595	19,153,383
<u>Financial assets</u>			
Participations in group companies	522,094	420,010	420,010
Total Fixed Assets	30,189,726	27,741,324	30,973,298
Current Assets			
<u>Inventories and similar</u>			
Finished goods and goods for resale	4,093,028	4,863,367	2,567,773
Advance payment to suppliers	2,798,327	12,036	276,062
	6,891,355	4,875,403	2,843,835
<u>Current Receivables</u>			
Accounts Receivable	2,886,783	867,052	460,788
Current Receivables from group companies	443,654	2,679,583	–
Current Tax Assets	–	352,257	219,880
Other current receivables	–	2,052,514	43,927,775
Prepaid expenses and accrued income	1,140,812	631,486	311,218
	4,471,248	6,582,892	44,919,661
<u>Cash and Bank Balances</u>	3,645,049	9,156,670	606,356
Total Current Assets	15,007,651	20,614,965	48,369,852
Total Assets	45,197,378	48,356,289	79,343,150

Balance Sheet – Dignitana AB, Parent Company, continued

SEK

STATEMENT OF FINANCIAL POSITION	2018-09-30	2017-09-30	2017-12-31
Equity and Liabilities			
Equity			
<u>Restricted equity</u>			
Share Capital (40,528,224 shares par value SEK 1, previous year 20,274,112)	40,548,224	20,274,112	20,274,112
Unregistered share capital	–	–	20,274,112
Fund for development expenses	2,635,796	2,635,796	2,635,796
	43,184,020	22,909,908	43,184,020
<u>Non-restricted equity</u>			
Other paid-in capital	7,994,421	32,711,766	32,835,766
Share premium reserves	–	–	22,301,523
Issue expense	–	–	(4,772,032)
Results for the period	(19,933,167)	(19,099,995)	(42,277,262)
	(11,938,747)	13,611,771	8,087,995
Total Equity	31,245,273	36,521,679	51,272,015
Current Liabilities			
Accounts payable	4,594,588	4,134,077	4,409,253
Other current liabilities	578,768	367,442	9,485,220
Liabilities to credit institutions	–	–	5,000,000
Current payable to group company	5,536,745	–	431,425
Accrued expenses and deferred income	2,211,987	2,333,091	8,745,237
Total current liabilities	12,922,088	6,834,610	28,071,135
Long Term Liabilities			
Liabilities to Credit Institutions	1,030,017	5,000,000	–
Total Equity and Liabilities	45,197,378	48,356,289	79,343,150

Policies for preparation of the financial report

Swedish Annual Accounts Act (1995:1554) and Swedish Accounting Standards Board General Recommendations BFNAR 2012:1 Annual reporting and consolidated financial statements.

Financial calendar

26 February 2019	2018 Year End Report
15 May 2019	Annual General Meeting
16 May 2019	Q1 Interim Report through 31 March 2019

Past financial reports are available at www.dignitana.se

Contact information

Dignitana AB

Traktorgården 3, 226 60 Lund
+46 (0) 46-16 30 90
www.dignitana.se
info@dignitana.se
investorrelations@dignitana.com

Certified Adviser

Erik Penser Bank
+46 (0) 8 463 8000
www.penser.se